ZUCALI, PAOLO ANDREA
ZUCALI, PAOLO ANDREA
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma
2013-01-01 Giovannetti, Elisa; Peters, Godefridus J; Zucali, Paolo A
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
2012-01-01 Bachner, M; Loriot, Y; Gross-Goupil, M; Zucali, P A; Horwich, A; Germa-Lluch, J-R; Kollmannsberger, C; Stoiber, F; Fléchon, A; Oechsle, K; Gillessen, S; Oldenburg, J; Cohn-Cedermark, G; Daugaard, G; Morelli, F; Sella, A; Harland, S; Kerst, M; Gampe, J; Dittrich, C; Fizazi, K; De Santis, M
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study
2020-01-01 Basso, U.; Paolieri, F.; Porta, C. G.; De Giorgi, U.; Bracarda, S.; Antonuzzo, L.; Atzori, F.; Cartenì, G.; Procopio, G.; Fratino, L.; D'Arcangelo, M.; Fornarini, G.; Zucali, P. A.; Cusmai, A.; Santoni, M.; Baldessari, C.; Naglieri, E.; Panni, S.; Zagonel, V.; Tortora, G.
[Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]
2000-01-01 Carnaghi, C; Zucali, P; Garassino, I
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors
2017-01-01 Deutsch, Eric; Moyal, Elizabeth Cohen-Jonathan; Gregorc, Vanesa; Zucali, Paolo Andrea; Menard, Jean; Soria, Jean-Charles; Kloos, Ioana; Hsu, Jeff; Luan, Ying; Liu, Emily; Vezan, Remus; Graef, Thorsten; Rivera, Sofia
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma
2020-01-01 Zucali, Pa; Perrino, M; de Vincenzo, F; Giordano, L; Cordua, N; D’Antonio, F; Santoro, A
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
2013-01-01 Santoro, A; Simonelli, M; Rodriguez-Lope, C; Zucali, P; Camacho, Lh; Granito, A; Senzer, N; Rimassa, L; Abbadessa, G; Schwartz, B; Lamar, M; Savage, Re; Bruix, J
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1
2016-01-01 Giovannetti, Elisa; Leon, Leticia G; Gómez, Valentina E; Zucali, Paolo A; Minutolo, Filippo; Peters, Godefridus J
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors
2014-01-01 Petrini, Iacopo; Meltzer, Paul S; Kim, In-Kyu; Lucchi, Marco; Park, Kang-Seo; Fontanini, Gabriella; Gao, James; Zucali, Paolo A; Calabrese, Fiorella; Favaretto, Adolfo; Rea, Federico; Rodriguez-Canales, Jaime; Walker, Robert L; Pineda, Marbin; Zhu, Yuelin J; Lau, Christopher; Killian, Keith J; Bilke, Sven; Voeller, Donna; Dakshanamurthy, Sivanesan; Wang, Yisong; Giaccone, Giuseppe
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
2004-01-01 Santoro, A.; Cavina, R.; Latteri, F.; Zucali, P. A.; Ginanni, V.; Campagnoli, E.; Ferrari, B.; Morenghi, E.; Pedicini, V.; Roncalli, M.; Alloisio, M.; Ravasi, G.; Soto Parra, H. J.
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas
2009-01-01 Simonelli, M; Banna, G; Navarria, P; Di Ieva, A; Zucali, P; De Vincenzo, F; Gaetani, P; Condorelli, R; Baena, Rry; Scorsetti, M; Santoro, A
Advances in drug treatments for mesothelioma
2022-01-01 Zucali, Paolo Andrea; De Vincenzo, Fabio; Perrino, Matteo; Digiacomo, Nunzio; Cordua, Nadia; D'Antonio, Federica; Borea, Federica; Fazio, Roberta; Pirozzi, Angelo; Santoro, Armando
Advances in the biology of malignant pleural mesothelioma
2011-01-01 Zucali, Pa; Ceresoli, Gl; De Vincenzo, F; Simonelli, M; Lorenzi, E; Gianoncelli, L; Santoro, A
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
2004-01-01 Parra, Hs; Cavina, R; Latteri, F; Zucali, Pa; Campagnoli, E; Morenghi, E; Grimaldi, Gc; Roncalli, M; Santoro, A
Anti-angiogenic therapies for malignant pleural mesothelioma
2012-01-01 Ceresoli, Giovanni Luca; Zucali, Paolo Andrea
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines
2011-01-01 León, Leticia G; Giovannetti, Elisa; Alecci, Claudia; Giancola, Fiorella; Funel, Niccola; Zucali, Paolo; Peters, Godefridus J; Padrón, José M
Assessment of tumor response in malignant pleural mesothelioma
2007-01-01 Ceresoli, Gl; Chiti, A; Zucali, Pa; Cappuzzo, F; De Vincenzo, F; Cavina, R; Rodari, M; Poretti, D; Lutman, Fr; Santoro, A
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib
2010-01-01 Giovannetti, E; Zucali, PAOLO ANDREA; Peters, G J; Cortesi, F; D'Incecco, A; Smit, Ef.; Falcone, A; Burgers, J A; Santoro, A; Danesi, R; Giaccone, G; Tibaldi, C; Ri, G E
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors
2015-01-01 Serpico, D; Trama, A; Haspinger, E R; Agustoni, F; Botta, L; Berardi, R; Palmieri, G; Zucali, P; Gallucci, R; Broggini, M; Gatta, G; Pastorino, U; Pelosi, G; de Braud, F; Garassino, M C
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
2022-01-01 Conforti, Fabio; Zucali, Paolo Andrea; Pala, Laura; Catania, Chiara; Bagnardi, Vincenzo; Sala, Isabella; Della Vigna, Paolo; Perrino, Matteo; Zagami, Paola; Corti, Chiara; Stucchi, Sara; Barberis, Massimo; Guerini-Rocco, Elena; Di Venosa, Benedetta; De Vincenzo, Fabio; Cordua, Nadia; Santoro, Armando; Giaccone, Giuseppe; Martino De Pas, Tommaso
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma | 1-gen-2013 | Giovannetti, Elisa; Peters, Godefridus J; Zucali, Paolo A | |
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial | 1-gen-2012 | Bachner, M; Loriot, Y; Gross-Goupil, M; Zucali, P A; Horwich, A; Germa-Lluch, J-R; Kollmannsberger, C; Stoiber, F; Fléchon, A; Oechsle, K; Gillessen, S; Oldenburg, J; Cohn-Cedermark, G; Daugaard, G; Morelli, F; Sella, A; Harland, S; Kerst, M; Gampe, J; Dittrich, C; Fizazi, K; De Santis, M | |
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study | 1-gen-2020 | Basso, U.; Paolieri, F.; Porta, C. G.; De Giorgi, U.; Bracarda, S.; Antonuzzo, L.; Atzori, F.; Cartenì, G.; Procopio, G.; Fratino, L.; D'Arcangelo, M.; Fornarini, G.; Zucali, P. A.; Cusmai, A.; Santoni, M.; Baldessari, C.; Naglieri, E.; Panni, S.; Zagonel, V.; Tortora, G. | |
[Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?] | 1-gen-2000 | Carnaghi, C; Zucali, P; Garassino, I | |
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors | 1-gen-2017 | Deutsch, Eric; Moyal, Elizabeth Cohen-Jonathan; Gregorc, Vanesa; Zucali, Paolo Andrea; Menard, Jean; Soria, Jean-Charles; Kloos, Ioana; Hsu, Jeff; Luan, Ying; Liu, Emily; Vezan, Remus; Graef, Thorsten; Rivera, Sofia | |
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma | 1-gen-2020 | Zucali, Pa; Perrino, M; de Vincenzo, F; Giordano, L; Cordua, N; D’Antonio, F; Santoro, A | |
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis | 1-gen-2013 | Santoro, A; Simonelli, M; Rodriguez-Lope, C; Zucali, P; Camacho, Lh; Granito, A; Senzer, N; Rimassa, L; Abbadessa, G; Schwartz, B; Lamar, M; Savage, Re; Bruix, J | |
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 | 1-gen-2016 | Giovannetti, Elisa; Leon, Leticia G; Gómez, Valentina E; Zucali, Paolo A; Minutolo, Filippo; Peters, Godefridus J | |
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors | 1-gen-2014 | Petrini, Iacopo; Meltzer, Paul S; Kim, In-Kyu; Lucchi, Marco; Park, Kang-Seo; Fontanini, Gabriella; Gao, James; Zucali, Paolo A; Calabrese, Fiorella; Favaretto, Adolfo; Rea, Federico; Rodriguez-Canales, Jaime; Walker, Robert L; Pineda, Marbin; Zhu, Yuelin J; Lau, Christopher; Killian, Keith J; Bilke, Sven; Voeller, Donna; Dakshanamurthy, Sivanesan; Wang, Yisong; Giaccone, Giuseppe | |
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer | 1-gen-2004 | Santoro, A.; Cavina, R.; Latteri, F.; Zucali, P. A.; Ginanni, V.; Campagnoli, E.; Ferrari, B.; Morenghi, E.; Pedicini, V.; Roncalli, M.; Alloisio, M.; Ravasi, G.; Soto Parra, H. J. | |
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas | 1-gen-2009 | Simonelli, M; Banna, G; Navarria, P; Di Ieva, A; Zucali, P; De Vincenzo, F; Gaetani, P; Condorelli, R; Baena, Rry; Scorsetti, M; Santoro, A | |
Advances in drug treatments for mesothelioma | 1-gen-2022 | Zucali, Paolo Andrea; De Vincenzo, Fabio; Perrino, Matteo; Digiacomo, Nunzio; Cordua, Nadia; D'Antonio, Federica; Borea, Federica; Fazio, Roberta; Pirozzi, Angelo; Santoro, Armando | |
Advances in the biology of malignant pleural mesothelioma | 1-gen-2011 | Zucali, Pa; Ceresoli, Gl; De Vincenzo, F; Simonelli, M; Lorenzi, E; Gianoncelli, L; Santoro, A | |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer | 1-gen-2004 | Parra, Hs; Cavina, R; Latteri, F; Zucali, Pa; Campagnoli, E; Morenghi, E; Grimaldi, Gc; Roncalli, M; Santoro, A | |
Anti-angiogenic therapies for malignant pleural mesothelioma | 1-gen-2012 | Ceresoli, Giovanni Luca; Zucali, Paolo Andrea | |
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines | 1-gen-2011 | León, Leticia G; Giovannetti, Elisa; Alecci, Claudia; Giancola, Fiorella; Funel, Niccola; Zucali, Paolo; Peters, Godefridus J; Padrón, José M | |
Assessment of tumor response in malignant pleural mesothelioma | 1-gen-2007 | Ceresoli, Gl; Chiti, A; Zucali, Pa; Cappuzzo, F; De Vincenzo, F; Cavina, R; Rodari, M; Poretti, D; Lutman, Fr; Santoro, A | |
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib | 1-gen-2010 | Giovannetti, E; Zucali, PAOLO ANDREA; Peters, G J; Cortesi, F; D'Incecco, A; Smit, Ef.; Falcone, A; Burgers, J A; Santoro, A; Danesi, R; Giaccone, G; Tibaldi, C; Ri, G E | |
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors | 1-gen-2015 | Serpico, D; Trama, A; Haspinger, E R; Agustoni, F; Botta, L; Berardi, R; Palmieri, G; Zucali, P; Gallucci, R; Broggini, M; Gatta, G; Pastorino, U; Pelosi, G; de Braud, F; Garassino, M C | |
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial | 1-gen-2022 | Conforti, Fabio; Zucali, Paolo Andrea; Pala, Laura; Catania, Chiara; Bagnardi, Vincenzo; Sala, Isabella; Della Vigna, Paolo; Perrino, Matteo; Zagami, Paola; Corti, Chiara; Stucchi, Sara; Barberis, Massimo; Guerini-Rocco, Elena; Di Venosa, Benedetta; De Vincenzo, Fabio; Cordua, Nadia; Santoro, Armando; Giaccone, Giuseppe; Martino De Pas, Tommaso |